載入中
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
前收盤價
US$3.85
+US$0.04 · +1.05%
盤中時間採用ET。市場資料可能有所延遲。
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
日內區間
目前US$3.85
52週區間
目前US$3.85
盤中時間採用ET。市場資料可能有所延遲。
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
日內區間
目前US$3.85
52週區間
目前US$3.85
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（CHF） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 497萬 CHF | 703.8萬 CHF | 1.9億 CHF | 933萬 CHF |
| 銷貨成本 | 204.86萬 CHF | 4750.4萬 CHF | 4784.4萬 CHF | 5074.9萬 CHF | 5571.8萬 CHF |
| 毛利 | −204.86萬 CHF | −4253.4萬 CHF | −4080.6萬 CHF | 1.39億 CHF | −4638.8萬 CHF |
| 研究與開發 | 4019.4萬 CHF | 4860.4萬 CHF | 4878.4萬 CHF | 5074.9萬 CHF | 5571.8萬 CHF |
| 銷售、一般及管理費用 | 1487.1萬 CHF | 1716.4萬 CHF | 1899.5萬 CHF | 2182.2萬 CHF | 1690.6萬 CHF |
| 營業費用 | 5089.42萬 CHF | 1868.3萬 CHF | 2030.2萬 CHF | 7294.3萬 CHF | 7274.9萬 CHF |
| 利息收入 | 152.2萬 CHF | 338.4萬 CHF | 427.9萬 CHF | 119.57萬 CHF | 10.83萬 CHF |
| 利息支出 | 1.8萬 CHF | 2.5萬 CHF | 4.9萬 CHF | 64.81萬 CHF | 60.81萬 CHF |
| 折舊和攤銷 | 214.4萬 CHF | 236.9萬 CHF | 242萬 CHF | 238.8萬 CHF | 256.5萬 CHF |
| 營業利益 | −5812.4萬 CHF | −6121.7萬 CHF | −6110.8萬 CHF | 1.17億 CHF | −6341.8萬 CHF |
| 淨利 | −6165.1萬 CHF | −5404.3萬 CHF | −6198.4萬 CHF | 1.18億 CHF | −6378.5萬 CHF |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$21.00
上漲空間 445.45%評級樣本有限，僅4項
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
